Disease-free survival · People with squamous cell carcinoma of the oral cavity or oropharynx
It is very uncertain whether tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus… changes disease-free survival compared with standard therapy alone (radiotherapy or chemoradiotherapy) (very low certainty).
1 finding from 1 review
Locoregional control · People with squamous cell carcinoma of the oral cavity or oropharynx
It is very uncertain whether tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus… changes locoregional control compared with standard therapy alone (radiotherapy or chemoradiotherapy) (very low certainty).
1 finding from 1 review
Oral mucositis (moderate to severe) · Patients with osteosarcoma (bone cancer) receiving high-dose methotrexate, vincristine and leucovorin
1 finding from 1 review
Oral mucositis (moderate to severe). Not estimable - no participants had developed moderate or severe oral mucositis by the fourth day after chemotherapy when the data were reported (Zhang 2011, Analysis 4.2, subgroup…
1 study · 81 participants
GRADE not reported
Locoregional control · People with squamous cell carcinoma of the oral cavity or oropharynx
EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard… probably leads to lower locoregional control compared with standard therapy alone (radiotherapy or chemoradiotherapy) (moderate certainty).
1 finding from 1 review
Locoregional control · People with squamous cell carcinoma of the oral cavity or oropharynx
1 finding from 1 review
Quality of life · People with squamous cell carcinoma of the oral cavity or oropharynx
1 finding from 1 review
Only one study (Bonner 2006, 424 participants) comprehensively assessed quality of life using EORTC QLQ-C30 (v3.0) and QLQ-H&N35; no statistically significant difference between groups for global health status or any…
1 study · 424 participants
GRADE not reported
Patient satisfaction · Patients with missing teeth and an atrophic posterior maxilla, with residual bone height between 4 and 9 mm below the maxillary sinus
1 finding from 1 review
Treatment costs · Patients with missing teeth and an atrophic posterior maxilla, with residual bone height between 4 and 9 mm below the maxillary sinus
The review found no eligible studies for this question.
1 finding from 1 review
Treatment costs: no trials reported this outcome (extrapolated by the review authors). Additional costs were associated with the long-implant + augmentation group (extra surgery, biomaterial, barrier, hospitalisation…
0 studies
No studies found
Patient preference · Patients with missing teeth and an atrophic posterior maxilla, with residual bone height between 4 and 9 mm below the maxillary sinus
1 finding from 1 review
Complications (at treated sites) · Patients with missing teeth and an atrophic posterior maxilla, with residual bone height between 4 and 9 mm below the maxillary sinus
Maxillary sinus lift (augmentation) with long implants may leads to higher complications (at treated sites) compared with short implants (5 to 8.5 mm) without sinus augmentation (low certainty).
1 finding from 1 review
Augmentation procedure failure · Patients with missing teeth and an atrophic posterior maxilla, with residual bone height between 4 and 9 mm below the maxillary sinus
1 finding from 1 review
Implant failure · Patients with missing teeth and an atrophic posterior maxilla, with residual bone height between 4 and 9 mm below the maxillary sinus
Maxillary sinus lift (augmentation) with long implants showed no clear difference in implant failure compared with short implants (5 to 8.5 mm) without sinus augmentation (moderate certainty).
1 finding from 1 review
Implant failure · Patients undergoing one-stage crestal maxillary sinus lift without bone grafts (baseline residual bone height about 6.5 mm)
Hand mallet (osteotomes) showed no clear difference in implant failure compared with electric mallet; GRADE not reported.
1 finding from 1 review
Augmentation procedure failure · Patients undergoing one-stage crestal maxillary sinus lift without bone grafts (baseline residual bone height about 6.5 mm)
1 finding from 1 review
Complication at augmented site · Patients undergoing one-stage crestal maxillary sinus lift without bone grafts (baseline residual bone height about 6.5 mm)
Hand mallet (osteotomes) showed no clear difference in complications at augmented site compared with electric mallet; GRADE not reported.
1 finding from 1 review
Prosthesis failure · Patients undergoing one-stage crestal maxillary sinus lift without bone grafts (baseline residual bone height about 6.5 mm)
1 finding from 1 review
Crespi 2012 (parallel, 40 per group): prosthesis failures 0/40 versus 0/40; none.
1 study · 80 participants
GRADE not reported
Prosthesis failure · Patients with missing teeth and an atrophic posterior maxilla, with residual bone height between 4 and 9 mm below the maxillary sinus
Maxillary sinus lift (augmentation) with long implants showed no clear difference in prosthesis failure compared with short implants (5 to 8.5 mm) without sinus augmentation (moderate certainty).
1 finding from 1 review
Restoration of function (occlusion) · Adults (16 to 68 years) with mandibular fractures excluding condylar involvement
1 finding from 1 review
Restoration of the original occlusion, assessed visually, was similar in both groups (P>0.05); occlusal correction was not achieved in one participant in the two-lag-screws group. Surrogate/proxy outcome.
1 study
GRADE not reported
Non-union · Adults with fractures of the mandibular angle
Transbuccal miniplate combined with intraoral approach showed no clear difference in non-union compared with intraoral approach alone; GRADE not reported.
1 finding from 1 review
Restoration of function (malocclusion; interincisor mouth opening) · Adults with fractures of the mandibular angle
1 finding from 1 review